Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026 BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs. Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chemistry.

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $9, representing a -3.12% change from its previous close.

Amazon delivered robust Q4 2025 results, with accelerating revenue growth and AWS leading at 23.6% YoY. AMZN's operating margin reached a historic high of 11.8%, driven by strong AWS profitability at a 35% margin. The stock sold off after management guided FY 2026 CapEx to $200bn, 50% above FY 2025 and exceeding operating cash flow by $60bn.

Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.23 at the closing of the latest trading day, reflecting a -9.06% change compared to its last close.

Allegiant Travel Company demonstrates disciplined capacity management and cost control, supporting a "Buy" rating and strong post-earnings stock performance. Q4 2025 results show a swing to profitability with a 10.2% operating margin, despite modest margin compression and reduced unit revenues. ALGT targets stable capacity and efficiency gains in 2026, leveraging Boeing 737 MAX upgrades to drive cost improvements without diluting unit revenues.

Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratory Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis GPT-5-driven autonomous lab executed over 36,000 experiments Ginkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven science BOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free protein synthesis reaction costs by 40% relative to state of the art, while running 36,000 experimental conditions across six iterative cycles.

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $8.27, denoting a -5.92% move from the preceding trading day.

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.31, signifying a -1.27% move from its prior day's close.

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.02, marking a -6.36% move from the previous day.